
The immediate backdrop is the March 2026 US–Israel military campaign against Iran: in early March the United States and Israel coordinated strikes against Iranian power-generation facilities, air-defence installations and declared military infrastructure, and Iranian armed responses throughout 2026 have occurred as reactions to those strikes.
That campaign built on a pattern of direct exchanges between Israel and Iran that intensified in 2024, when a series of Israeli strikes on Iranian-linked facilities prompted successive Iranian counterstrikes and reciprocal Israeli actions through the year.
Iran is facing shortages of hundreds of medicines after war, international sanctions and soaring inflation disrupted supply chains and constrained imports, leaving essential drugs intermittently unavailable.
Euronews reports authorities are prioritising distribution and hunting for alternative suppliers while patients face delays, higher prices and resort to black‑market purchases; Yahoo News Australia and Yahoo News Canada carried similar summaries of that reporting.
Government officials, according to the coverage, are trying to manage limited supplies by rationing and logistical prioritisation, but outlets emphasize the immediate consequence for patients who cannot reliably obtain medicines.
The reporting does not provide precise lists of which drugs are affected or quantified stock levels; instead it focuses on the broad scope of shortages and the coping measures being deployed.
Sources agree on causes — war, sanctions and inflation — but differ in depth: euronews provides specific consequences for patients and supply responses, while the Yahoo News summaries present the central claim in headline form.
Confirmed facts in the pack are limited to the shortages, the cited causes, and reported patient behaviors; claims about alternative suppliers and distribution prioritisation come from authorities as described in the sources and are presented as such.
The articles do not identify exact dates for when specific shortages began, named pharmaceutical companies, or detailed casualty-equivalent impacts from the shortages, leaving gaps that complicate assessing long-term health effects and which medicines are most at risk.